Abbvie Inc

Change company Symbol lookup

Select an option...

ABBV Abbvie Inc

AIMC Altra Industrial Motion Corp

TRST TrustCo Bank Corp N Y

VNE Veoneer Inc

ZS Zscaler Inc

SSTK Shutterstock Inc

SUI Sun Communities Inc

SLB Schlumberger NV

NWHUF NorthWest Healthcare Properties REIT

BBI Brickell Biotech Inc

Go

According to Google's Health boss David Feinberg... over one billion people a day search Google for health concerns. But, what if, instead... they could "consult" a phone app with the power of hundreds of doctors? Mentioned in today's commentary...(PR Newswire)

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is continuing its commitment to breast health, awareness, restoration, and research in support of breast cancer awareness month. For the month of October and into 2022, Allergan Aesthetics , The...(PR Newswire)

AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis (nr-axSpA), showing upadacitinib (RINVOQ(R); 15 mg, once daily) met...(PR Newswire)

AbbVie (NYSE: ABBV) will announce its third-quarter 2021 financial results on Friday, October 29, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through...(PR Newswire)

AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI(R)) in Crohn's disease, upadacitinib (RINVOQ(R)) in ulcerative colitis and HUMIRA(R) (adalimumab) in inflammatory bowel disease (IBD) will be presented as live...(PR Newswire)

AbbVie (NYSE: ABBV) today announced new analyses from the Phase 3 RINVOQ(R) (upadacitinib) atopic dermatitis clinical trial program to be presented at the 30th European Academy of Dermatology and Venereology (EADV) Virtual Congress. One analysis...(PR Newswire)

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved QULIPTA(TM) (atogepant) for the preventive treatment of episodic migraine in adults.1 QULIPTA is the first and only oral calcitonin gene-related peptide...(PR Newswire)

From texting mishaps to lost reading glasses, the impact of age-related blurry near vision, or difficulty seeing things up close, on daily life can be pervasive. People who struggle with this may have presbyopia, which affects most adults over 40...(PR Newswire)

AbbVie (NYSE: ABBV) today announced it will present 27 abstracts across its dermatology portfolio, including new analyses evaluating the safety and efficacy of RINVOQ(R) (upadacitinib) in atopic dermatitis and new data on SKYRIZI(R) (risankizumab)...(PR Newswire)

AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for risankizumab-rzaa (600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an...(PR Newswire)

AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for the treatment of adults with moderately to severely active ulcerative...(PR Newswire)

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. The cash dividend is payable November 15, 2021 to stockholders of record at the close of business on October 15, 2021. (PR Newswire)

AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22. More than 20 abstracts...(PR Newswire)

AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Wednesday, September 15, 2021. Richard A. Gonzalez, chairman and chief executive officer, Michael Severino, M.D., vice chairman and...(PR Newswire)

AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced The Lancet published the results of the dose escalation part of the Phase 1/2 EPCORE(TM) NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating...(PR Newswire)

Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE(TM) NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating...(BusinessWire)

AbbVie (NYSE: ABBV) today announced that data from its migraine portfolio will be presented at the International Headache Congress 2021, held jointly this year by the International Headache Society and the European Headache Federation, from...(PR Newswire)

AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ(R) (upadacitinib), an oral, selective and reversible JAK inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and...(PR Newswire)

https://mma.prnewswire.com/media/1596472/Technavio___Forecast_and_Analysis_2021_2025.jpg Technavio has been monitoring the pruritus therapeutics market and it is poised to grow by USD 4.01 billion during 2021-2025, progressing at a CAGR of almost 6%...(PR Newswire)

AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine (NEJM) has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic...(PR Newswire)